Atossa Therapeutics

Atossa Therapeutics sold 1,363,637 common shares plus warrants, raising net proceeds of about $4.5 million before fees. The issued warrants entitle holders to buy additional shares and could generate up to $12 million in additional gross proceeds if exercised, although there is no guarantee those proceeds will be realized. The company intends to use the funds for clinical development of its product candidates, working capital and general corporate purposes; (Z)-Endoxifen is the lead candidate. Atossa reported a negative EBITDA of $39.58 million over the past twelve months and is consuming cash rapidly. » More on de.investing.com

Atossa Therapeutics announced a registered direct placement to raise US$4.5 million, after which the stock fell about 30% in premarket trading. The deal calls for the sale of 1,363,638 common shares at US$0.18 each plus warrants of series A and B covering 1,363,638 shares each; the warrants become exercisable six months after issuance (series A: 5.5‑year term, series B: 2‑year term). If fully exercised for cash, the warrants could generate up to US$12 million in additional gross proceeds, though exercise is not guaranteed. Rodman & Renshaw is acting as exclusive placement agent, with closing expected around June 12, 2026; net proceeds are intended for clinical development, working capital and general corporate purposes. » More on de.investing.com

Atossa announced that two abstracts on (Z)-endoxifen were accepted for the ASCO 2026 annual meeting. Preclinical data show that (Z)-endoxifen inhibits estrogen receptor signaling in breast cancer models with ESR1 mutations and reduces ER activity in MCF-7 cells to 16–26% of control levels, with activity against Y537N, Y537S and D538G. A second abstract describes the ongoing phase 2 EVANGELINE study (40 mg daily plus goserelin) in the neoadjuvant setting for premenopausal patients; the primary endpoint is reduction of Ki‑67 after four weeks. Atossa is a clinical biopharma company with a market capitalization of USD 42.63 million; the stock fell 57.68% over six months. » More on de.investing.com